Greenwich LifeSciences up on positive DSMB feedback for cancer study

Greenwich Lifesciences

14/02/2024 18:23

** Shares of cancer therapy developer Greenwich LifeSciences
 GLSI.O  rise 34.4% to $11.17  
    ** Co says an independent Data Safety Monitoring Board
(DSMB) of the U.S. National Institutes of Health recommended no
modification to a late-stage study testing its experimental
immunotherapy to prevent breast cancer recurrences in patients
who have previously undergone surgery
    ** No serious adverse events related to the therapy,
GLSI-100, have been reported to date - GLSI
    ** Co anticipates adding up to 10 trial sites in the U.S. in
2024
    ** Including session's gains, stock down ~30% in last 12
months

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))